GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

Merck said Enflonsia is administered as a single ... their first RSV season if their mothers did not receive a maternal RSV vaccine.

Robert F. Kennedy Jr. faced questions from Congress about his own potential conflicts of interest during a confirmation ...